Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
15 participants
INTERVENTIONAL
2014-07-31
2020-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Deep Inspiration Breath Hold as Primary Strategy for Locally Advanced Lung Cancer Radiotherapy
NCT02540499
Image Guided and Breathing Adapted Radiotherapy of Early Stage Lung Cancer
NCT00910546
Tumor Response in Hypofractionated Radiotherapy
NCT02854449
Markerless Image Guidance Using Intrafraction Kolovoltage X-ray Imaging for Lung Cancer Radiotherapy
NCT04310891
Detection of Circulating Biomarkers of Immunogenic Cell Death
NCT02921854
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Treatment
BioXmark
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BioXmark
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically confirmed non-small cell lung cancer (NSCLC)
* Stage T1-4N1-3M0
* Performance status ≤ 2
* Inoperable
* FEV1 ≥ 1 l
* Ability to hold deep inspiration breathhold for \> 15 seconds
* Accepting treatment at Rigshospitalet
* Eligible for concomitant chemo-radiotherapy
* If a woman is of childbearing potential, a negative pregnancy test must be documented
* Ability to understand the given information
* Signed written consent for inclusion into the study
Exclusion Criteria
* Allergy to Iodine or iodine based contrast
* In the opinion of the investigator, the patient will not be able to follow the study procedures or is considered not eligible for other reasons
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Steen Riisgaard Mortensen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Steen Riisgaard Mortensen
MD
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Rigshospitalet, Denmark
Copenhagen, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
310-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.